{"links":{"html":"https://www.erudio.com/reports/lungtime-c01-nct05549037","json":"https://www.erudio.com/reports/lungtime-c01-nct05549037.json","markdown":"https://www.erudio.com/reports/lungtime-c01-nct05549037.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"lungtime-c01-05549037"}},"request":"https://www.erudio.com/contact?report=lungtime-c01-05549037"},"offer":{"cited_commentary_sources":70,"verified_hcp_statements":237,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":62,"optional":true,"price_per_verified_person_usd":15,"price_usd":930,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"lungtime-c01-nct05549037"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=lungtime-c01-05549037","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/lungtime-c01-nct05549037","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T02:35:41.747773Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":1},"aspects":[{"claim_count":46,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":37,"title":"Primary endpoint: Progression-free survival (PFS)"},{"claim_count":9,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":8,"title":"Secondary endpoint: Objective Response Rate (ORR)"},{"claim_count":45,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":36,"title":"Secondary endpoint: Overall survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":0,"title":"Secondary endpoint: Duration of Response (DoR)"},{"claim_count":21,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":12,"title":"Population and setting"},{"claim_count":37,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":26,"title":"The comparison"},{"claim_count":20,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.interventions","source_count":16,"title":"Safety and tolerability"},{"claim_count":56,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":24,"title":"Design and conduct"},{"claim_count":44,"coverage":"discussed","id":"A1","source_count":15,"title":"Retraction, confidence in the results and clinical usability"},{"claim_count":21,"coverage":"discussed","id":"A2","source_count":12,"title":"Conflicting evidence and the i-TIMES comparison"},{"claim_count":58,"coverage":"discussed","id":"A3","source_count":34,"title":"Immune biology, pharmacology and alternative temporal explanations"},{"claim_count":25,"coverage":"discussed","id":"A4","source_count":13,"title":"Cutoff selection, individual circadian phase and first-dose timing"},{"claim_count":45,"coverage":"discussed","id":"A5","source_count":27,"title":"Practical uptake, capacity, delivery route and patient access"},{"claim_count":38,"coverage":"discussed","id":"A6","source_count":21,"title":"Scientific prominence, replication priorities and public trust"}],"counts":{"cited_sources":71,"claims_by_expression_type":{"comparison":11,"experience":4,"interpretation":80,"opinion":68,"primary_context":2,"question":20,"restatement":22,"uncertainty":18,"unspecified":12},"claims_by_kind":{"interpretation":2,"protocol_statement":2,"source_observation":233},"clinician_statements":108,"evidence_units":217,"findings":9,"organisational_accounts":6,"people_cited":79,"people_identity_verified":62,"people_total":80,"screened_sources":93,"verified_claims":237},"findings_index":[{"id":"F1","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":12},"has_counterview":true,"limitations":2,"links":{"context":3,"support":19},"ma_question":true,"named_voices":7,"passages":18,"sources":10,"sources_by_kind":{"commentary":8,"media":2}},"title":"Retraction limits clinical use of these results without resolving the underlying timing hypothesis"},{"id":"F2","structure":{"claims":44,"claims_by_group":{"comparisons":4,"experience":0,"questions":3,"restated":5,"views":32},"has_counterview":true,"limitations":2,"links":{"context":10,"support":47},"ma_question":true,"named_voices":8,"passages":27,"sources":9,"sources_by_kind":{"commentary":6,"media":3}},"title":"Criticism centers on prespecification, protocol chronology and data patterns—not effect-size surprise alone"},{"id":"F3","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":0,"questions":2,"restated":3,"views":10},"has_counterview":true,"limitations":2,"links":{"context":2,"support":22},"ma_question":true,"named_voices":10,"passages":21,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"i-TIMES prompted both timing skepticism and disagreement about what a null interpretation means"},{"id":"F4","structure":{"claims":47,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":6,"views":35},"has_counterview":true,"limitations":2,"links":{"context":1,"support":50},"ma_question":true,"named_voices":31,"passages":43,"sources":28,"sources_by_kind":{"commentary":25,"media":3}},"title":"Historical adoption views ranged from emphatic practice change to validation-first caution"},{"id":"F5","structure":{"claims":33,"claims_by_group":{"comparisons":1,"experience":0,"questions":11,"restated":3,"views":18},"has_counterview":true,"limitations":2,"links":{"context":2,"support":34},"ma_question":true,"named_voices":20,"passages":28,"sources":13,"sources_by_kind":{"commentary":11,"media":2}},"title":"Design and generalizability concerns include attribution to ICI versus co-timed chemotherapy"},{"id":"F6","structure":{"claims":52,"claims_by_group":{"comparisons":4,"experience":0,"questions":9,"restated":8,"views":31},"has_counterview":true,"limitations":2,"links":{"context":2,"support":55},"ma_question":true,"named_voices":37,"passages":51,"sources":32,"sources_by_kind":{"commentary":29,"media":3}},"title":"Circadian immune plausibility coexists with pharmacologic objections and alternative explanations"},{"id":"F7","structure":{"claims":26,"claims_by_group":{"comparisons":0,"experience":3,"questions":12,"restated":0,"views":11},"has_counterview":true,"limitations":2,"links":{"context":1,"support":26},"ma_question":true,"named_voices":15,"passages":24,"sources":13,"sources_by_kind":{"commentary":12,"media":1}},"title":"Before 15:00 is not synonymous with morning, circadian phase or the timing of every dose"},{"id":"F8","structure":{"claims":33,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":0,"views":29},"has_counterview":true,"limitations":3,"links":{"context":2,"support":34},"ma_question":true,"named_voices":24,"passages":34,"sources":25,"sources_by_kind":{"commentary":23,"media":2}},"title":"Cost-neutral treatment is not necessarily cost-neutral service delivery"},{"id":"F9","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":3,"questions":1,"restated":2,"views":8},"has_counterview":true,"limitations":2,"links":{"context":1,"support":14},"ma_question":true,"named_voices":10,"passages":14,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Actual scheduling preferences retained exceptions for access, attendance and treatment continuity"}],"medical_affairs_question":"How can timing research distinguish a reproducible benefit from protocol, assessment and patient-scheduling effects without delaying access to effective treatment?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Retraction changes the evidentiary status, not the scientific question"},{"id":"section-2","level":2,"title":"Integrity concerns require reconstructable methods and data, not a conclusion of fraud"},{"id":"section-3","level":2,"title":"Competing evidence does not have a single uncontested interpretation"},{"id":"section-4","level":2,"title":"Historical enthusiasm was emphatic, but thresholds for adoption differed"},{"id":"section-5","level":2,"title":"Design concerns extend beyond integrity to causal attribution and transportability"},{"id":"section-6","level":2,"title":"Immune correlates support hypotheses, while pharmacology and alternative mechanisms remain contested"},{"id":"section-7","level":2,"title":"The exposure question is clock time, biological phase and treatment initiation—not simply morning"},{"id":"section-8","level":2,"title":"Operational simplicity was disputed even when drug cost was unchanged"},{"id":"section-9","level":2,"title":"Patient access and continuity qualify early-treatment preferences"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":22},{"id":"F5","shared_claims":5},{"id":"F6","shared_claims":10},{"id":"F7","shared_claims":3},{"id":"F8","shared_claims":6},{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-free survival (PFS)"},{"findings":[{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":2}],"id":"T2","label":"Secondary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":22},{"id":"F5","shared_claims":5},{"id":"F6","shared_claims":11},{"id":"F7","shared_claims":4},{"id":"F8","shared_claims":7},{"id":"F9","shared_claims":1}],"id":"T3","label":"Secondary endpoint: Overall survival (OS)"},{"findings":[],"id":"T4","label":"Secondary endpoint: Duration of Response (DoR)"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":7},{"id":"F5","shared_claims":14},{"id":"F6","shared_claims":3},{"id":"F7","shared_claims":3},{"id":"F8","shared_claims":5},{"id":"F9","shared_claims":2}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":12},{"id":"F5","shared_claims":9},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":11},{"id":"F8","shared_claims":9},{"id":"F9","shared_claims":6}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":9},{"id":"F8","shared_claims":5},{"id":"F9","shared_claims":2}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":23},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":13},{"id":"F5","shared_claims":28},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":4},{"id":"F8","shared_claims":3},{"id":"F9","shared_claims":2}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T02:35:41.747773Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T02:46:28Z","record_hash":"466b47bcbbaa92db846267db5e579ac0196d8f78c8ef41e0804faf2f685be0bd","release_hash":"3368e006dc5fa3868c9b3d58d98bcc6a6086f2e059597e609369d68f25a6ec1a","report_id":"erudio-nct05549037","run_id":"96a1c96f-4d9e-4525-b2d7-5e9cd15ae06e","schema_version":"5.0","slug":"lungtime-c01-05549037","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on LungTIME-C01 in the sources reviewed for this edition leads to one open question: How can timing research distinguish a reproducible benefit from protocol, assessment and patient-scheduling effects without delaying access to effective treatment? Its leading findings: (1) retraction limits clinical use of these results without resolving the underlying timing hypothesis. (2) criticism centers on prespecification, protocol chronology and data patterns—not effect-size surprise alone. (3) i-TIMES prompted both timing skepticism and disagreement about what a null interpretation means. 6 more findings follow. 93 sources screened, 71 cited; not all HCPs or all public discussion.","meta_description":"93 sources screened · 237 verified statements (108 from clinicians verified by NPI or staff page) from 71 sources · 9 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-30T02:46:28Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":93},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on retraction-related uncertainty in the evidence supporting morning cancer-treatment scheduling.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","44 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are not a representative sample of HCP opinion. Search emphasis on the trial identifier and registered names may miss unnamed references or wording variants.","Forty-four potentially relevant sources without an explicit trial name were not read, and some passages in otherwise reviewed discussions were not fully assessed for clinician views.","The original results paper, complete protocol and patient-level data were not independently evaluated here. The registry supplies planned methods; numerical results and integrity concerns are attributed reports or interpretations.","Historical numerical summaries, follow-up durations, assessment descriptions and phase labels differ. They have not been combined into a single corrected efficacy estimate.","Retraction and editorial concerns do not independently establish fraud, a particular source of bias or exact equivalence between early and late administration.","Named account identity does not necessarily establish a clinical role. Unverified roles, institutional relays, automated-account commentary and unidentified narration are not counted as additional confirmed HCP perspectives.","Reposts, duplicated posts and multiple statements by one person do not establish independent corroboration or consensus.","No matching regulatory document for the combined registry intervention entry was available. Suggestions involving subcutaneous or home administration do not establish approval, equivalence or administration requirements.","No substantive commentary on duration of response was identified in the material reviewed."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":10,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":52,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":70,"methods":1},"count":71,"evidence_window":{"end":"2026-10-21","start":"2025-05-24"},"retrieval_snapshot":"2026-10-30T01:24:58.601837Z","timeline":[{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":16,"week":"2025-W23"},{"count":1,"week":"2025-W33"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2026-W03"},{"count":28,"week":"2026-W06"},{"count":4,"week":"2026-W08"},{"count":2,"week":"2026-W09"},{"count":3,"week":"2026-W13"},{"count":2,"week":"2026-W19"},{"count":7,"week":"2026-W26"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W31"},{"count":2,"week":"2026-W32"},{"count":2,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05549037:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05549037:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41629425","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6qsr3ebzrptzaycswv63nnh4-3mp2co45xyu2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6vo56vqh2erei7xqs2t5nqbu-3mey4qajk2u2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6vwezbhj7wwowu4sbur5npjk-3mdvab6kxb223","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3mdwa7s5il22i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-j4xpj44pu62wjc55imsxyxio-3mdxr2ajua22b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-s2kbtwkxjk7rrxebsoqzscwd-3mpitppqlxl2f","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-sndgq3xpohrrb2pmcx23f3qi-3mfckmj4cn42e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-viblu7bkcbeq4crwxnz2iwda-3lqn25l7c3k2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vlbpdban632brzgecx2wjol2-3ms6s2fi75g25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vlbpdban632brzgecx2wjol2-3msdotdcwhg2v","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7424256968053157889","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7424334324444991488","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7424405545811341312","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7424515820631883776","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7424874731562250243","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7424990258984927232","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7429603044029276160","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7430951780596727809","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7475698040411185152","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7476202685789188096","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:99b67c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925907391654003163:145112c3-2f20-4bd9-beb3-f98c02c9acf3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926230100950794603:528791b5-5c42-4261-ac8f-777b23834ec0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929533945139405018:e095001b-db63-4cbb-8d64-d4a19965c666","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929534006242017327:83eacc91-b262-4f5d-8779-ebea92e9de77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929534251575222762:f6391bda-2bf5-4133-b675-2e0bb8893a33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929534446140809460:b57f1846-1152-47cd-bf42-0b11ff015531","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929535596113846550:3053a4d3-5e62-4e43-84ee-7a04d997cf3a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929535996791603639:5eada89e-46e7-4af6-a11c-f3aca6e263f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929536282306216036:a8b4d0eb-4e4e-4505-9b2e-a602b5f5ed06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929537643794051350:ab740e83-adb1-46ab-aa23-a1e662eae619","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929539351639191702:3cf0af63-22c9-4a4a-836f-90433ad40628","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929541014080938088:4f48a077-9905-4558-b548-ad868af6ea5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929541829772394701:c26fe8ab-3b0c-494a-8181-88abedf39e0f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929548174609293624:39863bd4-8ddf-4249-8d81-15d1f151c2aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929571299048796177:f28ee6d0-01ca-4376-a75d-cf0056280e9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929709845328154934:0d665383-5d85-4095-a257-ab62ff44c287","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929712550880452989:74d5c2e3-b1d8-447d-a0b7-1df40e192649","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930307464223719810:c87f4077-4387-439e-8343-e8cd937dd5fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1931380448812486758:30603e21-19f8-416c-94d3-c5017cf4eb25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955648425392853401:416410c7-20fc-4672-8ec5-5ce46b9a6731","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957014764862820460:aab805a3-4e12-4cac-8eef-6c62685c4046","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010921233211363832:8852956e-4e5e-40bc-a988-c16f87b339c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018398495049167130:507dc39a-6dd7-400a-8757-5c7257ec9bd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018404409470804382:1601e377-da40-4ddc-a444-d79a0f023574","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018433086615343515:59799411-767a-4962-80f5-4442c4bace80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018473118923190378:b7f6316f-44c4-49ac-9871-822c083e4c8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018487625368420627:cb866868-af29-433a-80a7-c080d84ffb55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018499857825063365:ffcca92c-eea2-425b-a5b2-03ac3dd8d720","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018505769348440101:7ce28b10-190d-40c2-94b6-586bc43dafc2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018532020486553782:55119a6d-05fb-4725-a035-ef6022a364c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018566552136683827:ba1cc326-0b23-42ba-8d5c-d40ecd881319","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018644733556670791:c9c96b4a-8d63-4897-9ef9-0afe100ef735","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018702086725157177:70bc4ae0-5244-47e1-8633-d77ac2d804a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018717068573413848:54b68893-15b5-4e7d-96ba-6c8c070f83c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018718453360730358:04355f81-51a8-41d0-95bd-3817ba9f05f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018817696096288889:7660958b-f4a4-4a34-a7b9-853a8f252c9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018855708570321285:8b8c9828-be78-4388-9326-7561fd6f459a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018921251712991485:f811d38d-dc77-4e72-8862-0d72d64d25e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2019038131115430188:2c03d705-0662-4376-81dc-2f3649ebaa9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2019102589464486177:4110bef7-6a13-4fb0-b4fe-e2744ffc66a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2019218874567405969:8a5b1fd3-1c60-4414-a3cf-424b6d9f693c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2019645800620675506:bb223c5a-5163-4a97-bbc1-a4a8d827e52e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2020026818279936173:042948a6-bb20-4b13-949b-86881fd653e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2020026903017467930:7c116963-c359-4b26-b7bf-4aaf9bdda26e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2020234742487290331:1921e472-3df7-46fa-8ea4-3ebf82b8040e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2021365695901237735:c5005d78-f2d9-4e3f-a61d-9ce011711d88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2022308540237369496:c6ca3d71-01f9-43df-a559-bc66be67aeab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2023381854053941534:fdfb3bf4-6a20-4cfa-ad23-8cc9d27a357f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2024888046441709870:bdc09d09-4b0e-468c-9d6c-55780282139e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2025059154591731935:5edf9102-4735-4d2a-b360-ed17860930c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2030990743838335427:7a0c2e8b-d4a2-4c67-a352-bace0a3ed9fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033945833993863320:50b3d0e8-c3ae-4268-9e4c-41e374e193dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2036416005019500876:b00180bb-ff7d-4445-b882-fed04c401399","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2036478301263593567:15f370ba-79ab-469a-b4c3-b81b72b0d317","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2036487674450653353:fcf61c9d-d710-41d6-9752-b6fca62f1411","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037548037330100312:4e2d01b5-5f6e-405d-80c0-18ffe7a171cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052289920413192650:aff5ff8a-bfb8-45c8-89f1-6ec76f42904b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052772704105681119:7fb9c2cd-a1db-4109-9b71-b8d79c164bd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069864117649953212:f14a6182-f5bc-4c22-9ad8-a4655c9b9e79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069866403163943362:d2ebe8c6-0d89-4aef-ae06-6a7c43ea7e14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069876537160298821:1ae4f60c-8e1b-4c3c-9794-6238e92093a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069990290061205607:cdebc659-b77a-4284-8940-c305c598da9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2070256949451518095:c1a1d7a7-f196-4649-a4c0-cb08d4021028","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2070918098752823640:0a9f0482-0498-4bf7-9c0d-0fe9b95135f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084296998639866143:35a585b9-97b7-4cfa-980d-f88b511e78be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085033802900906127:f0b2eb9b-ab2a-4af4-a2ca-cf835abc3f9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110062711681999196:1e66c5ee-8e3e-4318-bec6-85626f8cbb27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113053323070959876:328fe1db-c17b-4a59-ad2f-b1970fa2c339","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113054270140625056:78edb091-f634-4523-8028-ba112d397d4b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GfqdJcz4Gb8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:cGwMmfiUnfw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uCcvv1bMmIs","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":10,"linkedin_post":10,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":69,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":93},"count":93,"evidence_window":{"end":"2026-10-21","start":"2025-05-23"},"retrieval_snapshot":"2026-10-30T01:24:58.601837Z","timeline":[{"count":2,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":18,"week":"2025-W23"},{"count":2,"week":"2025-W33"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2026-W03"},{"count":34,"week":"2026-W06"},{"count":2,"week":"2026-W07"},{"count":7,"week":"2026-W08"},{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W12"},{"count":4,"week":"2026-W13"},{"count":2,"week":"2026-W19"},{"count":9,"week":"2026-W26"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W31"},{"count":4,"week":"2026-W32"},{"count":1,"week":"2026-W42"},{"count":2,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pembrolizumab, sintilimab","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"LungTIME-C01","aliases":["LungTIME-C01","Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC","Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial"],"brief_title":"Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer"],"display_condition":"advanced non-small cell lung cancer","display_interventions":[["pembrolizumab"],["sintilimab"]],"enrollment":{"count":210,"type":"ACTUAL"},"interventions":[{"name":"Pembrolizumab, Sintilimab","synonyms":["time-of-day of administration of immunochemotherapy"],"type":"DRUG"}],"nct_id":"NCT05549037","official_title":"Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2024-12-02","type":"ACTUAL"},"primary_endpoints":[{"description":"To assess progression-free survival of patients treated by immunochemotherapy according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as first dose to first documented disease progression assessed by investigator or death due to any cause.","measure":"Progression-free survival (PFS)","timeFrame":"Time from first subject dose to study completion, or up to 36 month."}],"registered_date":{"date":"2022-09-22","type":"ACTUAL"},"registry_last_updated":"2026-06-03","registry_url":"https://clinicaltrials.gov/study/NCT05549037","short_name":"LungTIME-C01","short_name_basis":"registry_acronym","sponsor":"Hunan Province Tumor Hospital","start_date":{"date":"2022-09-23","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"INJECTION","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}